Phase I study of intravenous irinotecan using selective gastrointestinal decontamination [cefpodoxime] for prevention of diarrhea in relapsed or refractory pediatric solid tumors.

Trial Profile

Phase I study of intravenous irinotecan using selective gastrointestinal decontamination [cefpodoxime] for prevention of diarrhea in relapsed or refractory pediatric solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Irinotecan (Primary) ; Cefpodoxime
  • Indications Diarrhoea; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top